Enanta Pharmaceuticals | ENTA - Trade Creditors


Enanta Pharmaceuticals reported $1.88M in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
AbbVie USD 33.3B 29.71B Jun/2026
Amgen USD 20.83B 17.97B Sep/2026
Anika Therapeutics USD 6.24M 103K Jun/2026
Arrowhead Research USD 27.78M 2.97M Jun/2026
AstraZeneca USD 23.57B 679M Sep/2026
BioCryst Pharmaceuticals USD 14.58M 3.12M Sep/2026
Biogen USD 430.3M 26.4M Sep/2026
Bristol-Myers Squibb USD 4.63B 470M Sep/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Gilead Sciences USD 934M 260M Sep/2026
GlaxoSmithKline GBP 15.63B 1.29B Sep/2026
Halozyme Therapeutics USD 33.55M 9.94M Sep/2026
Heron Therapeutics USD 8.38M 3.27M Sep/2026
Immunic USD 11.01M 873K Mar/2026
Incyte USD 235.37M 1.16B Sep/2026
Insmed USD 84.3M 9.75M Sep/2026
Ionis Pharmaceuticals USD 27.11M 20.59M Sep/2026
J&J USD 9.32B 94M Sep/2026
Karyopharm Therapeutics USD 4.28M 276K Mar/2026
Ligand Pharmaceuticals USD 4.1M 5.31M Sep/2026
Merck USD 5.03B 1.2B Sep/2026
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
Novartis USD 4.24B 15M Sep/2026
Novavax USD 24.94M 2.01M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
PTC Therapeutics USD 41.59M 1.14M Sep/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sarepta Therapeutics USD 45.7M 5.28M Sep/2026
Vertex Pharmaceuticals USD 3.71B 99.2M Sep/2026